Abstract: Power sources that enable in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body power sources of the invention include a solid support, a first high surface area electrode and a second electrode. Embodiments of the in-power sources are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the power sources of the invention.

Abstract: The present invention relates to providing a detection device that has high robustness against a temperature change and a temporal change and that is capable of detecting a substance to be detected with high accuracy. The detection device of the present invention is a detection device that detects presence or an amount of a substance to be detected using an enhanced electric field based on surface plasmon resonance, the detection device having a light projecting unit for irradiating a metal film of a detection chip held by a chip holder with excitation light via a prism. The light projecting unit includes: a light source; a diaphragm for regulating an amount of light from the light source; and a conjugate optical system that optically conjugates an opening portion of the diaphragm and a region of the metal film irradiated with the excitation light.

Abstract: The present invention provides a medical device containing a cake composition comprising aripiprazole as an active ingredient and capable of suppressing agglomeration of aripiprazole in a suspension obtained by resuspending a freeze-dried substance; and a cake composition comprising aripiprazole as an active ingredient. The present invention relates to a medical device containing, in a storage container whose inner wall is treated with silicone, a freeze-dried cake composition comprising separately prepared aripiprazole as an active ingredient, wherein there is a space between the inner wall and the cake composition; and a cake composition comprising aripiprazole as an active ingredient and having a strength of 5 to 100 N.

Abstract: The present invention provides a combination drug for the treatment of a malignant tumor comprising 2-((1R,2R,4S)-2-amino-7-azabicyclo[2.2.1]heptan-7-yl)-5-(3,4-dichloro-2-methyl-2H-indazol-5-yl)-3-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one or a pharmaceutically acceptable salt thereof, and at least one additional compound having an antitumor effect or at least one pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising both the active ingredients.

Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.

Abstract: The present invention provides a novel compound having an excellent antitumor effect stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: [in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.

Abstract: An analysis method for detecting an amount of a substance by irradiating an analysis chip containing the substance and detecting a quantity of light output from the analysis chip. The analysis method including irradiating an incident surface of the analysis chip and another surface adjacent to the incident surface with detection light while changing a relative position of the detection light with respect to the analysis chip, detecting reflected light from the incident surface of the analysis chip, and acquiring information on a position of the analysis chip from a relationship between a quantity of the reflected light detected and the relative position. The analysis method determines if the analysis chip is abnormal when a quantity of target reflected light is equal to or lower than a predetermined light quantity.

Abstract: Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: Transbody communication systems employing communication channels are provided. Various aspects include, for example, an in vivo transmitter to transmit an encoded signal; a transbody functionality module to facilitate communication of the encoded signal; and a receiver to receive the encoded signal. Methods and apparatus are also provided.

Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: A production method for a genetically modified megakaryocyte, the method including a step of introducing a CRISPR-associated (Cas) family protein and guide RNA (gRNA) into a megakaryocyte to modify a subject gene, in which the Cas family protein and the gRNA to be introduced into the megakaryocyte in the step form a complex beforehand. This production method is useful as a technique for producing a genetically modified megakaryocyte and a modified platelet.

Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases.

Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: Provided is a temperature control system applied to an apparatus for analyzing a sample using a pipette nozzle and a reaction container, including a pipette tip temperature controller that heats a pipette tip which is fitted on the pipette nozzle and aspirates or discharges liquid and a reaction container temperature controller that heats the reaction container. The pipette tip temperature controller heats, in a concentrated manner, at least a distal end portion of the pipette tip of the pipette nozzle located at a predetermined heating position with hot air emitted from a heat source and is configured such that a distal end is capable of arriving at the reaction container by lowering the pipette nozzle from the heating position.

Abstract: Provided is a temperature control system applied to an apparatus for analyzing a sample using a pipette nozzle and a reaction container, including a pipette tip temperature controller that heats a pipette tip which is fitted on the pipette nozzle and aspirates or discharges liquid and a reaction container temperature controller that heats the reaction container. The pipette tip temperature controller heats, in a concentrated manner, at least a distal end portion of the pipette tip of the pipette nozzle located at a predetermined heating position with hot air emitted from a heat source and is configured such that a distal end is capable of arriving at the reaction container by lowering the pipette nozzle from the heating position.

Abstract: A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

Abstract: The present disclosure includes an anti-hGDF15 antibody that binds to an epitope of hGDF15 comprising the amino acid sequence of DHCPLGPGRCCRLH (SEQ ID NO: 3) and uses thereof.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.